Theravance Biopharma, Inc. Operating Income
Theravance Biopharma, Inc. (TBPH) reported Operating Income of -$8.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Theravance Biopharma, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$8.28M.
- Theravance Biopharma, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$9.48M.
- Theravance Biopharma, Inc. operating income (loss) for the quarter ending 2025-12-31 was $20.01M.
- Theravance Biopharma, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$6.46M.
- Theravance Biopharma, Inc. operating income (loss) for fiscal 2025 was -$3.60M.
- Theravance Biopharma, Inc. operating income (loss) for fiscal 2024 was -$46.95M.
- Theravance Biopharma, Inc. operating income (loss) for fiscal 2023 was -$56.03M.
- Theravance Biopharma, Inc. operating income (loss) for fiscal 2022 was -$91.96M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.28M 10-Q · filed 2026-08-11 | -$17.76M 10-Q · filed 2026-08-11 | $2.25M derived: sum of 3 quarters · filed 2026-08-11 | -$4.20M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$9.48M 10-Q · filed 2026-05-07 | $10.53M derived: sum of 2 quarters · filed 2026-05-07 | $4.07M derived: sum of 3 quarters · filed 2026-05-07 | $1.35M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $20.01M 10-K · filed 2026-03-23 | $13.56M derived: sum of 2 quarters · filed 2026-03-23 | $10.83M derived: sum of 3 quarters · filed 2026-08-11 | -$3.60M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$6.46M 10-K · filed 2026-03-23 | -$9.18M derived: sum of 2 quarters · filed 2026-08-11 | -$23.61M 10-Q · filed 2025-11-12 | -$32.81M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$2.73M 10-Q · filed 2026-08-11 | -$17.16M 10-Q · filed 2026-08-11 | -$26.36M derived: sum of 3 quarters · filed 2026-08-11 | -$37.20M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$14.43M 10-Q · filed 2026-05-07 | -$23.63M derived: sum of 2 quarters · filed 2026-05-07 | -$34.47M derived: sum of 3 quarters · filed 2026-05-07 | -$50.18M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$9.20M 10-K · filed 2026-03-23 | -$20.04M derived: sum of 2 quarters · filed 2026-03-23 | -$35.74M derived: sum of 3 quarters · filed 2026-03-23 | -$46.95M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | -$10.84M 10-K · filed 2026-03-23 | -$26.54M derived: sum of 2 quarters · filed 2026-03-23 | -$37.75M 10-Q · filed 2025-11-12 | -$43.99M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2024-06-30 | -$15.71M 10-K · filed 2026-03-23 | -$26.91M 10-Q · filed 2025-08-13 | -$33.15M derived: sum of 3 quarters · filed 2026-03-23 | -$41.91M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2024-03-31 | -$11.21M 10-K · filed 2026-03-23 | -$17.45M derived: sum of 2 quarters · filed 2026-03-23 | -$26.21M derived: sum of 3 quarters · filed 2026-03-23 | -$42.33M derived: sum of 4 quarters · filed 2026-03-23 | |||
| 2023-12-31 | -$6.24M 10-K · filed 2025-03-07 | -$15.00M derived: sum of 2 quarters · filed 2025-03-07 | -$31.12M derived: sum of 3 quarters · filed 2025-03-07 | -$56.03M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | -$8.76M 10-K · filed 2025-03-07 | -$24.88M derived: sum of 2 quarters · filed 2025-03-07 | -$49.80M 10-Q · filed 2024-11-14 | -$67.23M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2023-06-30 | -$16.12M 10-K · filed 2025-03-07 | -$41.03M 10-Q · filed 2024-08-08 | -$58.47M derived: sum of 3 quarters · filed 2025-03-07 | -$67.61M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2023-03-31 | -$24.91M 10-K · filed 2025-03-07 | -$42.34M derived: sum of 2 quarters · filed 2025-03-07 | -$51.49M derived: sum of 3 quarters · filed 2025-03-07 | -$78.37M derived: sum of 4 quarters · filed 2025-03-07 | |||
| 2022-12-31 | -$17.43M 10-K · filed 2024-03-01 | -$26.58M derived: sum of 2 quarters · filed 2024-03-01 | -$53.45M derived: sum of 3 quarters · filed 2024-03-01 | -$91.96M 10-K · filed 2024-03-01 | |||
| 2022-09-30 | -$9.14M 10-K · filed 2024-03-01 | -$14.20M 10-Q · filed 2022-11-09 | -$36.02M derived: sum of 2 quarters · filed 2024-03-01 | -$74.53M 10-Q · filed 2023-11-09 | -$130.69M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-06-30 | -$26.88M 10-K · filed 2024-03-01 | -$60.32M 10-Q · filed 2023-08-09 | -$65.38M 10-Q · filed 2022-08-08 | -$121.55M derived: sum of 3 quarters · filed 2024-03-01 | -$175.16M derived: sum of 4 quarters · filed 2024-03-01 | ||
| 2022-03-31 | -$38.50M 10-K · filed 2024-03-01 | -$94.67M derived: sum of 2 quarters · filed 2024-03-01 | -$148.28M derived: sum of 3 quarters · filed 2024-03-01 | -$212.39M derived: sum of 4 quarters · filed 2024-03-01 | |||
| 2021-12-31 | -$56.17M 10-K · filed 2023-03-01 | -$109.78M derived: sum of 2 quarters · filed 2023-03-01 | -$173.89M derived: sum of 3 quarters · filed 2023-03-01 | -$257.78M 10-K · filed 2023-03-01 | |||
| 2021-09-30 | -$53.62M 10-K · filed 2023-03-01 | -$117.72M derived: sum of 2 quarters · filed 2023-03-01 | -$201.62M 10-Q · filed 2022-11-09 | -$278.11M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | -$64.11M 10-K · filed 2023-03-01 | -$148.00M 10-Q · filed 2022-08-08 | -$224.49M derived: sum of 3 quarters · filed 2023-03-01 | -$301.11M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | -$83.89M 10-K · filed 2023-03-01 | -$160.38M derived: sum of 2 quarters · filed 2023-03-01 | -$237.00M derived: sum of 3 quarters · filed 2023-03-01 | -$309.17M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$76.49M 10-K · filed 2022-02-28 | -$153.10M derived: sum of 2 quarters · filed 2022-02-28 | -$225.28M derived: sum of 3 quarters · filed 2022-02-28 | -$297.63M 10-K · filed 2023-03-01 | -$297.76M 10-K · filed 2021-02-26 | ||
| 2020-09-30 | -$76.61M 10-K · filed 2022-02-28 | -$148.79M derived: sum of 2 quarters · filed 2022-02-28 | -$221.27M 10-Q · filed 2021-11-08 | -$291.84M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | -$72.18M 10-K · filed 2022-02-28 | -$144.65M 10-Q · filed 2021-08-05 | -$215.22M derived: sum of 3 quarters · filed 2022-02-28 | -$280.43M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$72.48M 10-K · filed 2022-02-28 | -$143.05M derived: sum of 2 quarters · filed 2022-02-28 | -$208.25M derived: sum of 3 quarters · filed 2022-02-28 | -$250.72M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | -$70.57M 10-K · filed 2021-02-26 | -$135.77M derived: sum of 2 quarters · filed 2021-02-26 | -$178.25M derived: sum of 3 quarters · filed 2021-02-26 | -$251.91M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$65.20M 10-K · filed 2021-02-26 | -$107.68M derived: sum of 2 quarters · filed 2021-02-26 | -$181.34M 10-Q · filed 2020-11-09 | -$243.96M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-06-30 | -$42.48M 10-K · filed 2021-02-26 | -$116.14M 10-Q · filed 2020-08-10 | -$178.76M derived: sum of 3 quarters · filed 2021-02-26 | -$241.21M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2019-03-31 | -$73.67M 10-K · filed 2021-02-26 | -$136.29M derived: sum of 2 quarters · filed 2021-02-26 | -$198.74M derived: sum of 3 quarters · filed 2021-02-26 | -$247.44M derived: sum of 4 quarters · filed 2021-02-26 | |||
| 2018-12-31 | -$62.62M 10-K · filed 2020-02-27 | -$125.07M derived: sum of 2 quarters · filed 2020-02-27 | -$173.78M derived: sum of 3 quarters · filed 2020-02-27 | -$238.75M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | -$62.45M 10-K · filed 2020-02-27 | -$111.15M derived: sum of 2 quarters · filed 2020-02-27 | -$176.13M 10-Q · filed 2019-11-08 | -$255.31M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | -$48.70M 10-K · filed 2020-02-27 | -$113.68M 10-Q · filed 2019-08-05 | -$192.86M derived: sum of 3 quarters · filed 2020-02-27 | -$249.85M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | -$64.98M 10-K · filed 2020-02-27 | -$144.15M derived: sum of 2 quarters · filed 2020-02-27 | -$201.15M derived: sum of 3 quarters · filed 2020-02-27 | -$266.27M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | -$79.18M 10-K · filed 2019-02-28 | -$136.17M derived: sum of 2 quarters · filed 2019-02-28 | -$201.29M derived: sum of 3 quarters · filed 2019-02-28 | -$260.12M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$57.00M 10-K · filed 2019-02-28 | -$122.12M derived: sum of 2 quarters · filed 2019-02-28 | -$180.95M 10-Q · filed 2018-11-08 | -$238.78M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-06-30 | -$65.12M 10-K · filed 2019-02-28 | -$123.95M 10-Q · filed 2018-08-02 | -$181.78M derived: sum of 3 quarters · filed 2019-02-28 | -$215.28M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2017-03-31 | -$58.83M 10-K · filed 2019-02-28 | -$116.66M derived: sum of 2 quarters · filed 2019-02-28 | -$150.16M derived: sum of 3 quarters · filed 2019-02-28 | -$197.65M derived: sum of 4 quarters · filed 2019-02-28 | |||
| 2016-12-31 | -$57.83M 10-K · filed 2018-02-28 | -$91.33M derived: sum of 2 quarters · filed 2018-02-28 | -$138.82M derived: sum of 3 quarters · filed 2018-02-28 | -$180.47M 10-K · filed 2019-02-28 | |||
| 2016-09-30 | -$33.49M 10-K · filed 2018-02-28 | -$80.99M derived: sum of 2 quarters · filed 2018-02-28 | -$122.63M 10-Q · filed 2017-11-08 | -$178.41M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-06-30 | -$47.50M 10-K · filed 2018-02-28 | -$89.14M 10-Q · filed 2017-08-09 | -$144.91M derived: sum of 3 quarters · filed 2018-02-28 | -$188.01M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2016-03-31 | -$41.64M 10-K · filed 2018-02-28 | -$97.42M derived: sum of 2 quarters · filed 2018-02-28 | -$140.51M derived: sum of 3 quarters · filed 2018-02-28 | -$185.80M derived: sum of 4 quarters · filed 2018-02-28 | |||
| 2015-12-31 | -$55.77M 10-K · filed 2017-03-01 | -$98.87M derived: sum of 2 quarters · filed 2017-03-01 | -$144.16M derived: sum of 3 quarters · filed 2017-03-01 | -$181.90M 10-K · filed 2018-02-28 | |||
| 2015-09-30 | -$43.09M 10-K · filed 2017-03-01 | -$88.39M derived: sum of 2 quarters · filed 2017-03-01 | -$126.13M 10-Q · filed 2016-11-09 | -$191.88M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | -$45.29M 10-K · filed 2017-03-01 | -$83.03M 10-Q · filed 2016-08-09 | -$148.78M derived: sum of 3 quarters · filed 2017-03-01 | -$198.84M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | -$37.74M 10-K · filed 2017-03-01 | -$103.49M derived: sum of 2 quarters · filed 2017-03-01 | -$153.55M derived: sum of 3 quarters · filed 2017-03-01 | -$210.26M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | -$65.75M 10-K · filed 2016-03-11 | -$115.81M derived: sum of 2 quarters · filed 2016-03-11 | -$172.52M derived: sum of 3 quarters · filed 2016-03-11 | -$232.54M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | -$50.06M 10-K · filed 2016-03-11 | -$106.77M derived: sum of 2 quarters · filed 2016-03-11 | -$166.79M 10-Q · filed 2015-11-12 | -$210.87M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-06-30 | -$56.71M 10-K · filed 2016-03-11 | -$116.72M 10-Q · filed 2015-08-13 | -$160.80M derived: sum of 3 quarters · filed 2016-03-11 | -$201.88M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2014-03-31 | -$60.02M 10-K · filed 2016-03-11 | -$104.10M derived: sum of 2 quarters · filed 2016-03-11 | -$145.18M derived: sum of 3 quarters · filed 2016-03-11 | -$184.13M derived: sum of 4 quarters · filed 2016-03-11 | |||
| 2013-12-31 | -$44.08M 10-K · filed 2015-03-13 | -$85.16M derived: sum of 2 quarters · filed 2015-03-13 | -$124.11M derived: sum of 3 quarters · filed 2015-03-13 | -$156.28M 10-K · filed 2016-03-11 | |||
| 2013-09-30 | -$41.08M 10-K · filed 2015-03-13 | -$80.03M derived: sum of 2 quarters · filed 2015-03-13 | -$112.20M 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | -$38.95M 10-K · filed 2015-03-13 | -$71.13M 10-Q · filed 2014-08-14 | |||||
| 2013-03-31 | -$32.17M 10-K · filed 2015-03-13 | ||||||
| 2012-12-31 | -$9.57M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |